Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez

Showing results (181-190 of 231) with videos related to

Pageof 24
Sort By:
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
The Pediatric Infectious Disease Journal|August 21, 2025
Urinary Cytomegalovirus Load at Birth as a Predictor of Sequelae in Congenital Cytomegalovirus InfectionMaría Ríos-Barnés, Roberto Pedrero, Clàudia Fortuny, et al.
Leukemia|August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialThierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
Frontiers in Nutrition|September 29, 2025
Correction: Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, <i>B. infantis</i> LMG11588, and <i>B. lactis</i> CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trialJean-Charles Picaud, Olivier Claris, Mercedes Gil-Campos, et al.
Frontiers in Nutrition|August 7, 2025
Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, <i>B. infantis</i> LMG11588, and <i>B. lactis</i> CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trialJean-Charles Picaud, Olivier Claris, Mercedes Gil-Campos, et al.
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Future Oncology (London, England)|March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study designAjay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Animal Reproduction Science|December 16, 2025
Suboptimal responses to E2/P4-based timed AI protocols compromise pregnancy outcomes in fertile beef cattle: Roles of ovulation timing and semen viabilityCésar Augusto Pinzón-Osorio, Thomaz Kranen Cunha, German Holguin-Sanabria, et al.
Pageof 24

Showing results (181-190 of 231) with videos related to

Sort By:
Pageof 24
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
The Pediatric Infectious Disease Journal|August 21, 2025
Urinary Cytomegalovirus Load at Birth as a Predictor of Sequelae in Congenital Cytomegalovirus InfectionMaría Ríos-Barnés, Roberto Pedrero, Clàudia Fortuny, et al.
Leukemia|August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialThierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
Frontiers in Nutrition|September 29, 2025
Correction: Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, <i>B. infantis</i> LMG11588, and <i>B. lactis</i> CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trialJean-Charles Picaud, Olivier Claris, Mercedes Gil-Campos, et al.
Frontiers in Nutrition|August 7, 2025
Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, <i>B. infantis</i> LMG11588, and <i>B. lactis</i> CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trialJean-Charles Picaud, Olivier Claris, Mercedes Gil-Campos, et al.
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Future Oncology (London, England)|March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study designAjay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Animal Reproduction Science|December 16, 2025
Suboptimal responses to E2/P4-based timed AI protocols compromise pregnancy outcomes in fertile beef cattle: Roles of ovulation timing and semen viabilityCésar Augusto Pinzón-Osorio, Thomaz Kranen Cunha, German Holguin-Sanabria, et al.
Pageof 24